| Excerpt | Reference |
|---|
| "The pathogenesis of uterine leiomyoma is controversial." | ( Fujii, S, 1992) |
| "Uterine fibroids are the commonest tumors of the female genital tract." | ( Adelberger, V; Breckwoldt, M; Geisthövel, F; Wieacker, P, 1990) |
| "The growth of uterine leiomyoma is regulated not only by the estrogen levels in blood, but also by estrogen production in the tumor itself." | ( Honjo, H; Kitawaki, J; Naito, K; Okada, H; Urabe, M; Yamamoto, T, 1990) |
| "Human uterine leiomyoma is a benign tumor and its development is closely related to estrogen." | ( Honjo, H; Kitawaki, J; Naitoh, K; Okada, H; Urabe, M; Yamamoto, T, 1990) |
| "Prolapsed submucous fibroids are not uncommon, and patients present with a vaginal mass which is often necrotic and infected." | ( Riley, P, 1982) |
| "Uterine fibroids are the most common solid pelvic tumor in women and in these last years their management has been deeply reviewed." | ( Colacurci, N; De Placido, G; Locci, M; Montemagno, U; Zullo, F, 1993) |
| "Submucous fibroids are a significant cause of subfertility." | ( Goswamy, K; Narayan, R, 1994) |
| "Bleeding from uterine leiomyoma is a rare cause of hemoperitoneum." | ( Cordero, PE; Danikas, D; Kotrotsios, J; Sills, C; Theodorou, SJ, 1999) |
| "The development of uterine leiomyomas is associated with exposure to ovarian sex steroids, abnormal uterine bleeding is commonly seen in patients with leiomyomas, and fibroids require an increased vascular supply for their growth." | ( Boettger-Tong, H; Chiappetta, C; Huang, JC; Hyder, SM; Mäkelä, S; Nawaz, Z; Stancel, GM, 2000) |
| "However, uterine leiomyomas are a leading cause of morbidity, infertility, and hysterectomy in women." | ( Li, S; McLachlan, JA, 2001) |
| "Uterine leiomyomas (uterine fibroids) are sex-steroid dependent benign tumors." | ( Englund, K; Eriksson, H; Masironi, B; Sahlin, L; Wang, H; Wu, X, 2001) |
| "Fibroids are rare before menarche and usually regress after menopause, suggesting that growth factors affecting the growth of uterine smooth muscle cells and fibroblasts may mediate the estrogen effect." | ( Haney, AF, 1995) |
| "Uterine fibroids are hormonally responsive; estradiol and progesterone stimulate their growth, and gonadotrophin-releasing hormone agonists shrink them." | ( Atkinson, C; Chen, C; Lampe, JW; Scholes, D; Schwartz, SM; Wähälä, K, 2006) |
| "Uterine fibroids are benign tumors that arise from individual smooth muscle cells of the uterus." | ( Lingxia, X; Taixiang, W; Xiaoyan, C, 2007) |
| "Fibroids are benign neoplasms of myometrial smooth muscle cells (SMC)." | ( Rogers, PA; Vollenhoven, BJ; Zaitseva, M, 2007) |
| "Human uterine leiomyomas are very common smooth muscle cell tumors that occur in reproductive-age women and are the leading reason for performing hysterectomies." | ( Al-Hendy, A; Arafa, HM; Hamada, FM; Hassan, MH; Salama, SA, 2007) |
| "Uterine fibroids are benign tumors that arise from individual smooth muscle cells of the uterus." | ( Chen, X; Wu, T; Xie, L, 2007) |
| "Uterine fibroids are composed of altered collagen fibrils and represent an arrested response to injury-initiating fibrosis." | ( Behera, MA; Catherino, W; Feng, L; Jung, SH; Leppert, P; Yonish, B, 2007) |
| "Uterine fibroids are the most common tumours presenting in women." | ( Fleischer, R; Rogers, PA; Vollenhoven, BJ; Weston, GC, 2008) |
| "TM fibroids are stiffer than the TM myometrium/cervix, and TM polyps are softer." | ( Frank, GR; Hall, TJ; Hobson, MA; Jiang, J; Madsen, EL; Shi, H; Varghese, T, 2008) |
| "Uterine fibroids are the most common benign tumour of the female genital tract." | ( Okolo, S, 2008) |
| "Uterine fibroids are the most common non-malignant growths in women of childbearing age." | ( Cardini, F; Liu, JP; Xia, Y; Yang, H, 2009) |
| "Uterine fibroid is the most common tumor of female reproductive organs." | ( Agoulnik, AI; Agoulnik, IU; Anderson, ML; Burzawa, JK; Feng, S; Kovanci, E; Li, Z; Rajkovic, A; Tong, X; Troung, A, 2009) |
| "Although uterine leiomyomas are the most common gynaecological benign tumour and greatly affect reproductive health and well being, the pathophysiology and epidemiology of uterine leiomyomas are not well known." | ( Isobe, A; Kimura, T; Li, B; Sakata, M; Takeda, T; Tsuiji, K; Wakabayashi, A; Yaegashi, N, 2010) |
| "Leiomyomas or fibroids are the most frequently diagnosed tumors of the female genital tract, and their growth seems to be steroid-hormone dependent by a yet undetermined cellular and molecular mechanism." | ( Almeida, TA; Báez, D; Bello, AR; Dorta, I; García, C; Hernández, M; Montes de Oca, F; Reyes, R; Rodríguez, Y; Valladares, F, 2010) |
| "Submucous fibroids are common benign tumours responsible for menorrhagia, subfertility and miscarriage." | ( Ben-Nagi, J; Davies, A; Jurkovic, D; Lee, C; Mavrelos, D; Salim, R, 2010) |
| "Most women with uterine fibroids are likely to have less menstrual blood loss and higher serum levels of hemoglobin, hematocrit and ferritin after insertion of an LNG-IUD, despite some occurrences of irregular bleeding." | ( Curtis, KM; Jamieson, DJ; Marchbanks, PA; Tepper, NK; Whiteman, MK; Zapata, LB, 2010) |
| "Although uterine fibroids are among the most common gynecologic conditions affecting women in the United States, research on uterine fibroids is sparse." | ( Huber, LR; Martin, CL; Racine, EF; Thompson, ME, 2011) |
| "Uterine fibroids are the most common benign tumor of the female genital tract." | ( Chabowski, A; Knapp, P, 2012) |
| "Uterine fibroids are benign myometrial tumors that produce large quantities of extracellular matrix proteins." | ( Bahr, JM; Braundmeier, AG; Hales, DB; Machado, SA; Nowak, RA; Quade, BJ, 2012) |
| "Uterine fibroids are the most common benign uterine tumours present in women of reproductive age." | ( Orozco, LJ; Ramírez-Morera, A; Steed, A; Stone, P; Tristan, M, 2012) |
| "Uterine fibroids are benign tumours that arise from individual smooth muscle cells of the uterus." | ( Chen, XY; Deng, L; Wu, T; Xie, L; Yang, J, 2012) |
| "Uterine fibroids are the most common premenopausal benign uterine tumours." | ( Laopaiboon, M; Lumbiganon, P; Mol, BW; Sangkomkamhang, US, 2013) |
| "Uterine fibroids are the most common non-malignant growths in women of childbearing age." | ( Cardini, F; Liu, JP; Xia, Y; Yang, H, 2013) |
| "Fibroids are the most common benign tumors of reproductive-age women, with the genital tract being the most common site for tumors." | ( Dayal, S; Kumar, A; Verma, A, 2014) |
| "Uterine fibroids are the most common benign tumors of the female genital tract." | ( Biglia, N; Carinelli, S; D'Alonzo, M; Lo Monte, G; Maiorana, A; Marci, R, 2014) |
| "Uterine fibroids are a prevalent gynaecological condition in reproductive-aged women and are the commonest reason for hysterectomy." | ( Girling, JE; Holdsworth-Carson, SJ; Rogers, PA; Vollenhoven, BJ; Zaitseva, M, 2014) |
| "Uterine fibroids are the most common solid tumors found in women of reproductive age." | ( Cowan, BD; Sadarangani, A; Suo, G; Tang, W; Wang, JY, 2014) |
| "Uterine fibroids are the most common benign tumors in women of reproductive age." | ( Gadomska, H; Grzechocinska, B; Wielgos, M; Zygula, A, 2014) |
| "Uterine fibroids are the most common benign uterine tumors." | ( Dolmans, MM; Donnez, J; Donnez, O, 2014) |
| "Uterine fibroids are benign hormone-sensitive tumors of uterine smooth muscle cells leading to heavy menstrual bleeding and pelvic pain." | ( Gotteland, JP; Pohl, O; Zobrist, RH, 2015) |
| "Uterine fibroids are extremely common, and can cause significant morbidity, yet the exact cause of these tumors remains elusive and there are currently no long-term treatments available." | ( Bulun, SE; Moravek, MB, 2015) |
| "Uterine fibroids are the most common benign uterine tumors in women of reproductive age." | ( Koskas, M; Luton, D; Puchar, A, 2015) |
| "Fibroids are the most common tumor of the female reproductive tract, but approved medical treatments are limited." | ( Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH, 2016) |
| "Uterine fibroids are the most commonly encountered benign uterine tumors in women of reproductive age." | ( Courtoy, GE; Dolmans, MM; Donnez, J; Donnez, O, 2016) |
| "Uterine fibroid is the most common tumor in women of reproductive age." | ( Póka, R; Török, P, 2016) |
| "Uterine fibroids are the most common benign tumors of the uterus." | ( Brodowska, A; Marciniak, A; Nawrocka-Rutkowska, J; Starczewski, A; Szydłowska, I; Wiśniewska, B, 2016) |
| "Uterine fibroids are a common problem for reproductive-aged women, yet little comparative effectiveness research is available to guide treatment choice." | ( AbdElmagied, AM; Barnard, EP; Borah, BJ; Gorny, KR; Hesley, GK; Jacoby, VL; Kohi, MP; Laughlin-Tommaso, SK; Leppert, PC; Miller, MJ; Nieves, A; Peterson, LG; Price, TM; Stewart, EA; Vaughan, LE; Weaver, AL; Woodrum, DA, 2017) |
| "Uterine fibroids are smooth muscle tumours arising from the uterus." | ( Chow, TL; Murji, A; Sobel, ML; Whitaker, L, 2017) |
| "Uterine fibroids are the most common form of benign gynecological tumors in women of reproductive ages." | ( Barra, F; Ferrero, S; Vellone, VG, 2018) |
| "Uterine fibroids are common in women of reproductive age and can have a significant impact on quality of life and fertility." | ( Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S, 2018) |
| "Uterine fibroids are the most common pelvic solid tumors and common to 25% of women." | ( Ma, Y; Shao, X, 2017) |
| "Uterine fibroids are benign tumors within the uterine wall affecting women." | ( Arriagada, P; Donnez, J; Larrey, D; Marciniak, M, 2018) |
| "Uterine fibroids are the most frequent benign tumours in women of child-bearing age." | ( De Wilde, RL; Ebert, AD; Rabe, T; Roemer, T; Saenger, N; Tinneberg, HR; Wallwiener, M, 2018) |
| "Uterine fibroids are the most common tumors affecting premenopausal women, responsible for bleeding, pain, and reduced quality of life." | ( Courtoy, GE; Dolmans, MM; Donnez, J, 2019) |
| "Uterine fibroids are the most common form of benign gynaecological tumors in women of childbearing age Piecak et al." | ( Collinet, P; Cosson, M; Giraudet, G; Pécout, M; Rubod, C, 2019) |
| "Uterine fibroids are a common cause of abnormal uterine bleeding in adult women, but are extremely rare in the adolescent years." | ( Kumura, NDS; Siarezi, S, 2020) |
| "The majority of fibroids are asymptomatic and require no intervention or further investigations." | ( Allaire, C; Laberge, PY; Leyland, N; Murji, A; Singh, SS; Vilos, GA, 2019) |
| "Uterine fibroids are the commonest tumour of the female genital tract; about one third are symptomatic and require management." | ( Abdul, IF; Adesina, KT; Amadu, MB; Olarinoye, AO; Omokanye, LO, 2019) |
| "Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual bleeding." | ( Ackerman, RT; Al-Hendy, A; Archer, DF; Barnhart, KT; Bradley, LD; Carr, BR; Feinberg, EC; Hurtado, SM; Kim, J; Liu, R; Mabey, RG; Muneyyirci-Delale, O; Owens, CD; Poindexter, A; Puscheck, EE; Rodriguez-Ginorio, H; Schlaff, WD; Simon, JA; Soliman, AM; Stewart, EA; Watts, NB, 2020) |
| "Background Uterine leiomyoma is a benign tumour of the uterine smooth muscles associated with an elevated level of inflammatory cytokines." | ( Al-Taie, A; Albasry, Z; Mohammed, NH, 2020) |
| "Although uterine leiomyomas are the most common benign uterine tumors in women, there is no effective therapy that can also preserve the uterus and maintain fertility." | ( Choi, HJ; Hwang, WY; Jung, MH; Kim, EJ; Kim, KS; Lee, JW, 2020) |
| "Fibroids are the most common benign tumours found in the uterus and can cause various symptoms." | ( Bosmans, JE; Hehenkamp, WJK; Huirne, JAF; Middelkoop, MA; van der Weide, MCJ, 2021) |
| "Uterine fibroids are the most common benign neoplasms in women." | ( Blanco Sequeiros, R; Joronen, K; Komar, G; Otonkoski, S; Perheentupa, A; Sainio, T; Saunavaara, J; Suomi, V, 2020) |
| "Uterine fibroids are benign tumours that cause various complaints." | ( Bet, PM; Drenth, JPH; Hehenkamp, WJK; Huirne, JAF; Middelkoop, MA, 2021) |
| "Uterine fibroids are a common cause of heavy menstrual bleeding and pain." | ( Al-Hendy, A; Arjona Ferreira, JC; Critchley, HOD; Langenberg, AGM; Li, Y; Lukes, AS; McKain, L; Poindexter, AN; Stewart, EA; Venturella, R; Villarroel, C; Wagman, RB, 2021) |
| "Uterine myomas/fibroids are one of the most common benign tumors of the reproductive system in women." | ( Ghafarzadeh, M; Marzban Rad, Z; Shakarami, A; Yari, F, 2021) |
| "Uterine fibroids are frequently encountered in gynecology and are a therapeutic challenge." | ( Avilés Dorlhiac, R; Navarro Plazaola, N; Vega Chacana, M, 2021) |
| "The growth of uterine leiomyomas is regulated by progesterone, although the underlying molecular mechanisms are not fully understood." | ( Antsiferova, Y; Malyshkina, A; Nagornii, S; Rukavishnikov, K; Sotnikova, N; Voronin, D, 2021) |
| "Uterine fibroids are highly prevalent, collagen-rich, mechanically stiff, fibrotic tumors for which new therapeutic options are needed." | ( Afrin, S; Borahay, MA; Brennan, JT; Islam, MS; Jayes, FL; Leppert, PC; Segars, JH; Singh, B, 2021) |
| "Uterine fibroids are benign." | ( Bi, C; Jia, Y; Qiao, M; Wang, H, 2021) |
| "The growth of uterine leiomyomas is dependent on the levels of sex steroid hormones, and they usually shrink after menopause." | ( Asano, R; Hayashi, H; Shigeta, H; Tanioka, S; Wakabayashi, R, 2022) |
| "Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs." | ( Al-Hendy, A; Archer, D; Bestel, E; Bradley, L; Donnez, J; Garner, E; Gotteland, JP; Humberstone, A; Loumaye, E; Marsh, E; Petraglia, F; Stewart, EA; Taylor, HS; Terrill, P; Watts, N, 2022) |
| "Symptomatic uterine fibroids are burdensome to live with; they are associated with symptom-related distress, affect daily activities, and reduce health-related quality of life." | ( Al-Hendy, A; Hunsche, E; Li, Y; Lukes, AS; Stewart, EA; Venturella, R; Wagman, RB, 2023) |
| "Uterine fibroids are benign tumor of the uterus that often appear during child bearing ages." | ( Arzoo, S; Ferdous, NE; Khatun, R; Mahmood, S; Rahman, R; Tanzin, F; Yousuf, S, 2023) |
| "Uterine fibroids are the most common cause of unexplained infertility in reproductive-aged women." | ( Al-Hendy, A; Christman, GM; Flaminia, A; Flores, VA; González, F; Huang, H; Johnson, JJ; Segars, J; Siblini, H; Singh, B; Taylor, HS; Zhang, H, 2023) |
| "Uterine fibroids are highly prevalent, benign tumors." | ( Baird, DD; Harmon, QE; Langton, CR; Upson, K, 2023) |
| "Both keloids and fibroids are fibroproliferative conditions that have been reported to be more prevalent among Blacks than Whites, and they share similar fibrotic tissue structures, including extracellular matrix composition, gene expression, and protein profiles." | ( Baird, DD; Gerety, M; Harmon, QE; Langton, CR, 2023) |
| "Uterine fibroid is a common gynecological disorder that affects women of reproductive age and has emerged as a major public health concern." | ( Bhat, RG; K, VK; R, AP; Rao, BK, 2023) |
| "However, uterine fibroids are highly vascular tumors and, consequently, extremely susceptible to problems from myomectomy-related hemorrhage." | ( Abd-ElGawad, M; Abdel-Hakam, F; Abdelaziz, DFM; Abdelhamed, SA; Abdelmonem, H; Abdou, AM; Afiffi, IK; Bosilah, AH; Eldesouky, E; Elhalim, AEMA; Ellaban, M; Elrashedy, AA; Elsayed, HGA; Elsror, AGA; Farag, E; Kamel, MA; Marai, AAE; Marie, H; Mohammed, A; Shaaban, A, 2023) |
| "Uterine fibroids are very common with a prevalence of over 70%." | ( Aref-Adib, M; Odejinmi, F; Sim-Ifere, O, 2023) |
| Excerpt | Reference |
|---|
| "Twenty-seven patients with uterine fibroids were treated for 3 months with the GnRH-agonist goserelin prior to surgical myomectomy." | ( Deichert, U; Duda, V; Gesenhues, T; Hackenberg, R; Schmidt-Rhode, P; Schulz, KD, 1992) |
| "Thirty-five women with symptomatic fibroids were treated with monthly injections of 3." | ( Ayalon, D; Eckstein, N; Eshel, A; Feinstein, Y; Foldes, J; Limor, R; Statter, M; Steinberg, R; Vagman, I, 1992) |
| "Maximal diminution of uterine and fibroid size had been nearly completely reached within the first 12 weeks of therapy." | ( Bühler, K; Cirkel, U; Künzig, HJ; Mayer-Eichberger, D; Mettler, L; Ochs, H; Schindler, AE; Schneider, HP; Winkler, U; Zahradnik, HP, 1992) |
| "Ten pre-menopausal women with uterine leiomyoma were treated for 1 year with a monthly depot of luteinizing hormone-releasing hormone agonist (LHRA-a), goserelin, combined after the initial 3 months of treatment with conjugated oestrogens 0." | ( Blanchet, P; Friede, J; Lemay, A; Maheux, R; Pratt, X, 1991) |
| "Our data confirm a role of EGF also in fibroid growth and suggest that, the blood supply reduction associated with the volume reduction of these tumours, consequent to the GnRH-a treatment, could be EGF mediated." | ( Cucuccio, S; De Cecco, L; Leone, M; Messeni Leone, M; Valenzano-Menada, M; Venturini, PL, 1991) |
| "We examined 194 cases of uterine leiomyoma and adenomyosis who received total abdominal hysterectomy, in order to compare the effect of presurgical medical treatment such as with Buserelin, Danazol and Pill, on operative blood loss with non-treated group." | ( Baba, K; Itoyama, S; Kinoshita, K; Kojima, T; Morita, Y; Sakamoto, S; Takeda, S, 1991) |
| "In a patient harboring uterine leiomyomas, adversely affecting conception and pregnancy outcome, GnRHa treatment may be an initial approach allowing to avoid pelvic surgery." | ( Adamo, R; Artini, PG; Coukos, G; Genazzani, AR; Silferi, M; Volpe, A, 1991) |
| "The reduction in uterine and fibroid volume associated with the chronic administration of a gonadotropin-releasing hormone agonist (GnRH-a) is thought to be secondary to the analogue induced hypoestrogenic state." | ( Friedman, AJ; MacLaughlin, DT; Rein, MS; Stuart, JM, 1990) |
| "The secretion of IGF-I and IGF-II by fibroid explants obtained from women treated with the GnRH-a was significantly less than that in tissue obtained from placebo-treated controls (P less than ." | ( Friedman, AJ; Heffner, LJ; Pandian, MR; Rein, MS, 1990) |
| "There was no significant difference in fibroid shrinkage between the two administration routes." | ( Healy, DL; McDonald, J; Shekleton, P; Vollenhoven, BJ, 1990) |
| "After 6 months of treatment, a fibroid reduction of more than 30% of the initial volume was observed in 16 patients in the buserelin group and in 18 patients in the goserelin group." | ( Anserini, P; Costantini, S; De Cecco, L; Remorgida, V; Valenzano, M; Venturini, PL, 1990) |
| "Ten patients with uterine fibroids palpable abdominally were treated with the luteinizing hormone-releasing hormone (LHRH) agonist buserelin, administered intransally, 300 micrograms three times daily, for 6 months, and were then followed for a further 12 months." | ( Matta, WH; Nye, M; Shaw, RW, 1989) |
| "Twelve patients with uterine fibroids, who were due to undergo myomectomy, were treated preoperatively with the luteinising hormone-releasing hormone analogue, Zoladex." | ( Fieggan, AG; Pienaar, CA; Van der Spuy, ZM; Wood, MJ, 1989) |
| "Treatment of patients with fibromyomata by Zoladex produces suppression of ovarian function." | ( Baird, DT; Bramley, TA; Hawkins, TA; Lumsden, MA; West, CP, 1989) |
| "Improved diagnosis has made drug treatment of uterine fibroids more of a reality." | ( Baird, DT; Lumsden, MA; West, CP, 1989) |
| "Eleven women with uterine leiomyomas were treated with 800 micrograms of nafarelin per day for 6 months." | ( Andreyko, JL; Blumenfeld, Z; Hricak, H; Jaffe, RB; Marshall, LA; Monroe, SE, 1988) |
| "Uterine fibroids shrank after 8 or 10 weeks of buserelin administration, as assessed by ultrasound or gynecological examination." | ( Abbott, M; Baird, DT; Fraser, HM; Healy, DL; Lawson, SR, 1986) |
| "Nine women harboring uterine leiomyomas have been treated with subcutaneous injections and then with intranasal insufflation of luteinizing hormone-releasing hormone agonist for a total treatment period of 6 months." | ( Lemay, A; Maheux, R; Merat, P, 1987) |
| "Twenty-six women with uterine leiomyoma were treated for 6 months with subcutaneous injections of the luteinizing hormone-releasing hormone agonist buserelin." | ( Lemay, A; Maheux, R; Turcot-Lemay, L, 1988) |
| "In addition, primary, but neither fibromyoma nor coagulation defect-associated menorrhagia, can be treated by ibuprofen." | ( Mäkäräinen, L; Ylikorkala, O, 1986) |
| "One hundred and eighty cases of uterine fibroids out of the two hundred treated in a gynaecological unit in a 7-year period are reviewed." | ( Ihejerika, IJ; Omu, AE; Tabowei, G, 1984) |
| "Thirty-four perimenopausal women with uterine leiomyomas were treated with intramuscular injections of leuprolide acetate depot each 28 days for 6 cycles, and 12 of them after 168 days of no medication underwent a second 6-month therapy cycle." | ( Altieri, P; de Aloysio, D; Paltrinieri, F; Pretolani, G; Romeo, A, 1995) |
| "On 30 women suffering from uterine fibroids, the monthly subcutaneous administration of goserelin depot (3." | ( Angiolucci, M; Arangino, S; Cagnacci, A; Falqui, A; Melis, GB; Paoletti, AM; Soldani, R, 1994) |
| "Two cases of fibroid growth and endometrial proliferation in postmenopausal women on tamoxifen (anti-oestrogen) therapy for breast cancer are described." | ( Harding, K; Ugwumadu, AH, 1994) |
| "We observed eleven cases of uterine fibromyoma during treatment with tamoxifen which required hysterectomy due to increased tumour volume." | ( Dauplat, J; de Latour, M; Le Bouëdec, G, 1995) |
| "Our study suggests that pretreatment of uterine leiomyomata leads to a significant increase in the hormonal receptor concentration of these benign tumors." | ( Callies, R; Kato, K; Regidor, PA; Schindler, AE; Schmidt, M, 1995) |
| "Uterine and fibroid volumes were decreased in the goserelin acetate-treated patients by between 37% and 40% and 44% and 47%, respectively, compared with 7% decreases for both in the iron only group." | ( Benagiano, G; Cronjé, H; Fadini, R; Kivinen, ST; Klintorp, S; van der Spuy, ZM, 1996) |
| "In the patient with uterine leiomyomata and anemia, goserelin acetate in combination with iron therapy has shown significant advantages over the iron alone in restoring hematologic normality, decreasing uterine and fibroid volumes, and reducing operative blood loss." | ( Benagiano, G; Cronjé, H; Fadini, R; Kivinen, ST; Klintorp, S; van der Spuy, ZM, 1996) |
| "GnRHa treatment reduced the size of uterine leiomyomata and induced significant hyaline degeneration in tumor tissue." | ( Higashijima, T; Kataoka, A; Nishida, T; Yakushiji, M, 1996) |
| "Twenty-seven women with uterine leiomyomas were treated with a standard dose of triptorelin for 8 weeks." | ( Broekmans, FJ; Falke, TM; Heitbrink, MA; Hompes, PG; Netelenbos, CC; Roos, JC; Schoemaker, J, 1996) |
| "Those diagnosed as having submucous fibroids were treated with goserelin injections, hysteroscopic resection, or a combination of both." | ( Goswamy, K; Narayan, R, 1994) |
| "Between 1987 and 1993, 61 patients with uterine leiomyomata and sterility underwent 6 months' GnRH agonist treatment, in part with a surgical intervention." | ( Bühler, K; Gärtner, A; Kuhlmann, M; Regidor, PA; Schindler, AE; Schindler, EM, 1997) |
| "The size of the uterine fibroids was reevaluated on the end of the treatment." | ( Chryssikopoulos, A; Costomenos, D; Gregoriou, O; Konidaris, S; Papadias, C; Vitoratos, N, 1997) |
| "Cell proliferation and apoptosis in uterine leiomyoma were investigated during therapy with GnRH agonist (GnRHa)." | ( Mizutani, T; Nakamuro, K; Sugihara, A; Terada, N, 1998) |
| "In women with uterine fibroids, there was no significant change in either the PI or the RI with treatment and there was no significant reduction in menstrual blood loss." | ( Hardiman, P; Lakhani, KP; Marsh, MS; Purcell, W, 1998) |
| "Uterine and uterine leiomyomata sizes, lumbar spine bone mineral density, biochemical markers of bone metabolism, lipid profile, and myoma-related symptoms were measured at baseline and after 6 months of treatment." | ( Affinito, P; Nappi, C; Palomba, S; Tommaselli, GA, 1998) |
| "Women with large uterine leiomyomas traditionally have had just one choice for therapy--abdominal hysterectomy." | ( Saltiel, E, 1995) |
| "Since October 1996, at our fibroid center, we have been using the uterine artery embolization (UAE) procedure as a nonsurgical means to treat patients with fibroids and menorrhagia." | ( Berkowitz, RP; Hutchins, FL; Worthington-Kirsch, RL, 1999) |
| "The use of UAE to treat patients with fibroids and menorrhagia is relatively new." | ( Berkowitz, RP; Hutchins, FL; Worthington-Kirsch, RL, 1999) |
| "Twenty women (34-42 years) with uterine fibromyomas were treated with 400 mg/day of danazol for 4-month periods." | ( De Leo, V; la Marca, A; Morgante, G, 1999) |
| "Cell proliferation in uterine leiomyomas treated preoperatively with either nafarelin (400 microg/day) for 3 months (7 patients) or nafarelin plus hormone (oestradiol + norethisterone) add-back therapy (6 patients) was investigated by automatic image analysis of frozen tissue sections using immunohistochemistry with anti-proliferating cell nuclear antigen antibody." | ( Kivinen, S; Kujansuu, E; Rantala, I; Rintala, S; Teisala, K; Tuimala, R, 1999) |
| "The IGF-I mRNA value in fibroids from pregnant women was higher than in any other group and myometrium from pregnant women exhibited higher mRNA expression than myometrium from non-treated premenopausal women." | ( Blanck, A; Carlström, K; Englund, K; Gustavsson, I; Lindblom, B; Sjöblom, P, 2000) |
| "The conventional treatment of uterine leiomyomas, or fibroids, with gonadotropin-releasing hormone (GnRH) agonists is often associated with serious side effects, necessitating short-term, palliative use of this therapy." | ( Bischoff, ED; Burroughs, KD; Fuchs-Young, R; Gamage, SD; Gottardis, MM; Lamph, WW; Walker, CL, 2000) |
| "Eighty-seven women with symptomatic fibroids warranting surgical treatment and wanting to retain their uteri." | ( Liu, WM; Ng, HT; Wu, YC; Yen, YK; Yuan, CC, 2001) |
| "This study covered 29 women with uterine leiomyomas who were treated with a GnRH agonist before surgery." | ( Ichimura, T; Ishiko, O; Ito, F; Kawamura, N; Ogita, S; Takahashi, K; Tsujimura, A, 2001) |
| "(1) The reference treatment for uterine leiomyoma with major symptoms is surgery." | ( , 2001) |
| "Seventy postmenopausal women with uterine leiomyomas were enrolled and treated for 12 cycles of 28 days each with transdermal 17 beta-estradiol (E(2)) patches plus oral medroxyprogesterone acetate continuously added (group A) or with calcium carbonate (group B)." | ( Di Carlo, C; Mastrantonio, P; Noia, R; Palomba, S; Sena, T; Zullo, F, 2001) |
| "This study involved 42 women with uterine leiomyomas treated with a gonadotropin releasing hormone (GnRH) agonist before surgery." | ( Ishiko, O; Kawamura, N; Ogita, S; Takahashi, K, 2002) |
| "Thirty-nine patients suffering from uterine leiomyomas were treated with leuprorelin acetate depot 3." | ( De Falco, M; De Rosa, G; Di Lieto, A; Iannotti, F; Pollio, F; Salvatore, G; Scaramellino, M; Staibano, S, 2002) |
| "One hundred premenopausal women with uterine leiomyomas were treated with leuprolide acetate depot at a dosage of 3." | ( Colao, A; Lombardi, G; Mastrantonio, P; Morelli, M; Nappi, C; Orio, F; Palomba, S; Pellicano, M; Russo, T; Zullo, F, 2002) |
| "The IGF-I mRNA in both fibroids and myometrium in the proliferative phase was significantly higher than those after GnRH-a treatment." | ( Blanck, A; Englund, K; Lindblom, B; Sahlin, L; Wang, H; Wu, X, 2002) |
| "Forty-six women with menorrhagia for uterine leiomyomatosis were treated monthly with leuprolide acetate depot 3." | ( Ciociola, F; De Falco, M; De Rosa, G; Di Lieto, A; Iannotti, F; Pollio, F; Staibano, S, 2003) |
| "The percent reduction of fibroid volume at the 6th month correlated with the percent increase of uterine RI at the 3rd month of treatment (r=0." | ( Dendrinos, S; Kanelopoulos, N; Markussis, V; Oikonomou, A; Panagopoulos, P, 2003) |
| "GnRH agonist therapy is known to reduce uterine leiomyoma volume, although the molecular mechanisms responsible for this effect remain poorly understood." | ( Beguinot, F; Bifulco, G; Ferraioli, M; Miele, C; Nappi, C; Paturzo, F; Pellicano, M; Tommaselli, GA; Trencia, A, 2004) |
| "Fifty pre-menopausal women with uterine leiomyomas were treated with leuprolide acetate depot at dose of 3." | ( Cascella, T; Doldo, P; Falbo, A; Lombardi, G; Mastrantonio, P; Nappi, C; Orio, F; Palomba, S; Russo, T; Zullo, F, 2004) |
| "Sixty premenopausal women with uterine leiomyomata were enrolled in a randomized controlled design and intraoperatively treated with injection of bupivacaine plus epinephrine (group A) or saline solution (group B) during laparoscopic myomectomy." | ( Barletta, E; Corea, D; Doldo, P; Falbo, A; Palomba, S; Pellicano, M; Russo, T; Saraco, P; Zullo, F; Zupi, E, 2004) |
| "Women with endometriosis or fibroids also benefit from this treatment." | ( Hurskainen, R; Paavonen, J, 2004) |
| "Fibroid volume, fibroid symptoms, and quality-of-life scores were measured before treatment and 6 months after treatment." | ( Ehrenstein, T; Gedroyc, WM; Geschwind, JF; Gostout, B; Hengst, S; Hesley, G; Hindley, J; Hynnen, K; Hynyen, K; Inbar, Y; Itzchak, Y; Jolesz, F; Kim, HS; Kim, K; Macdanold, N; Mcdannold, N; Rabinovici, J; Regan, L; Shushan, A; Sklair-Levy, M; Stewart, E; Tempany, C, 2004) |
| "Seventy women with symptomatic uterine fibromatosis were treated for four months with leuprorelin acetate alone or plus tibolone." | ( De Falco, M; De Rosa, G; Di Lieto, A; Mansueto, G; Pollio, F; Staibano, S, 2005) |
| "A total of 125 qualified patients with uterine leiomyoma were randomly divided into either triptorelin group (63 cases) treated with 3." | ( Hu, LN; Yang, DZ; Zheng, SR; Zhou, YF, 2005) |
| "Treatment of uterine leiomyoma with triptorelin for 3 months is both effective and safe in Chinese women." | ( Hu, LN; Yang, DZ; Zheng, SR; Zhou, YF, 2005) |
| "These results suggest that uterine leiomyomas growth and differentiation might be modulated through PPARgamma receptors and that PPARgamma ligands may be of potential use for uterine leiomyoma treatment." | ( Bae, I; Cha, SD; Cho, CH; Jeon, DS; Kwon, KY; Kwon, SH; Nam, DH; Ramachandran, S; Shin, SJ; Song, DK, 2007) |
| "The ideal medical therapy for fibroids is, arguably, a tablet that is taken by mouth, once a day or, even better, once a week, with minimal, if any, side-effects, that induces fibroid regression and thus a resolution of symptoms rapidly, but without affecting fertility." | ( Manyonda, IT; Sankaran, S, 2008) |
| "The cell viability and proliferation of uterine leiomyoma cells were significantly reduced by ISL treatment in a dose-dependent manner." | ( Bae, I; Baek, SH; Cha, SD; Cho, CH; Kim, DC; Kwon, KY; Kwon, SH; Ramachandran, S, 2008) |
| "A significant decrease in fibroid tumours and uterine volume concomitant with better quality of life scores can be obtained with a daily administration of Mifepristone 5mg." | ( Akerman, G; Barranger, E; Desfeux, P; Malartic, C; Morel, O; Tulpin, L, 2008) |
| "Uterine fibroid embolization is an effective treatment alternative for uterine fibroids." | ( Chen, W; Guo, WB; Yang, JY; Zhuang, WQ, 2008) |
| "The main outcome measures of uterine and uterine leiomyoma sizes, serum FSH, LH, oestradiol concentrations, ovarian volumes and myoma-related symptoms were noted at baselines and once a month during treatment." | ( Celik, H; Gurates, B; Kilic, G; Kumru, S; Parmaksiz, C; Simsek, M, 2008) |
| "Imaging data were analyzed from 45 fibroids in 42 women treated with MRgFUS." | ( Fennessy, FM; Hynynen, K; Maier, SE; McDannold, N; Pilatou, MC; Stewart, EA; Tempany, CM, 2009) |
| "The genic expression of uterine leiomyomas changes in women who have had goserelin treatment when compared with nontreated patients." | ( Baracat, EC; Borsari, R; Bozzini, N; Hilário, SG; Junqueira, CR; Soares, JM, 2010) |
| "All these PRMs are effective in the treatment of uterine fibroids where they are associated with a reduction in pain, bleeding and improvement in quality of life and decrease in fibroid size." | ( Spitz, IM, 2009) |
| "In an effort to treat large uterine leiomyoma in symptomatic patients in the Gynecology Clinics of the Alzahra Teaching Hospital of Tabriz University of Medical Sciences, Tabriz, Iran, from September 2007 to November 2008, 60 candidates randomized to receive Diphereline 3." | ( Dastranj-Tabrizi, A; Farzadi, L; Gatrehsamani, F; Kazemi-Shishvan, M; Morteza, G; Ouladesahebmadarek, E; Sayyah-Melli, M; Tehrani-Gadim, S, 2009) |
| "The proliferation rate of uterine leiomyoma cells was suppressed after treatment with LNG at a minimum concentration of 10 mcg/mL." | ( Luo, L; Qiu, L; Xu, C; Xu, Q; Zhu, L, 2010) |
| "In order not to over treat uterine leiomyoma and to avoid overlooking uterine leiomyosarcoma, a highly reliable diagnostic method has been thought." | ( Han, JY; Hyun, IY; Lee, BI; Moon, YS; Park, JH, 2010) |
| "In the treatment of uterine fibroid embolization related pain, the use of embolics loaded with non-steroidal anti-inflammatory drugs (NSAID) relies on an efficient delivery and impregnation of the embolized tissue." | ( Bédouet, L; Bevilacqua, C; Laurent, A; Lewis, AL; Martin, P; Namur, J; Pelage, JP; Schwartz-Cornil, I; Verret, V; Wassef, M, 2011) |
| "Eighty-three women with uterine leiomyoma were assigned in open, parallel-group fashion to a no-treatment (control) group and a GnRH-agonist group." | ( Irahara, M; Kase, Y; Matsui, S; Matsuzaki, T; Tsuchiya, N; Uemura, H; Yamamoto, S; Yasui, T; Yuzurihara, M, 2011) |
| "We randomized uterine fibroid-bearing Eker rats for treatment with Ro 41-0960 (150 mg/kg/12 h) versus vehicle for 2 and 4 weeks." | ( Al-Hendy, A; Bahashwan, S; Fouad, H; Hassan, MH, 2011) |
| "Ro 41-0960-treated rats exhibited fibroid volumes of 86 ± 7% and 105 ± 12% of initial burden, at 2 and 4 weeks post-treatment, respectively, significantly lower than control group (240 ± 15% and 300 ± 18%; P< 0." | ( Al-Hendy, A; Bahashwan, S; Fouad, H; Hassan, MH, 2011) |
| "Shrinkage rates of uterine leiomyomas were positively correlated with expression levels of ER in women treated with GnRH-a and in postmenopausal women managed conservatively, and with VEGF expression in women treated with GnRH-a." | ( Asano, C; Ichimura, T; Ishiko, O; Kasai, M; Kawamura, N; Matsuda, M; Sumi, T; Sumikura, T, 2012) |
| "The majority of symptomatic uterine fibroids are currently treated by surgical interventions (myomectomy or hysterectomy) or radiological treatments (uterine artery embolisation or focussed ultrasound surgery)." | ( Manyonda, I; Talaulikar, VS, 2012) |
| "Human uterine leiomyoma cells were cultured and treated with dimethylsulfoxide (DMSO) or a gestrinone concentration gradient." | ( Cao, L; Cao, Y; Guo, X; Tu, R; Xie, S; Zhang, T; Zhou, J; Zhou, X; Zhu, Y, 2012) |
| "The average volume of the fibroids before GnRHa treatment was 647." | ( Asada, H; Furuya, M; Jinzaki, M; Kuribayashi, S; Okuda, S; Oshio, K; Tanimoto, A; Yoshimura, Y, 2012) |
| "Women with fibroids within reproductive age may consider UAE as a treatment option." | ( Danzer, H; Lee, C; McLucas, B; Wambach, C, 2013) |
| "In women with and without fibroids, mean MBL was reduced compared with placebo across all treatment cycles (p < 0." | ( Adomako, TL; Baker, J; Eder, S; Gersten, J; Mabey, RG, 2013) |
| "An immortalized human uterine fibroid cell line (HuLM) and/or primary human uterine fibroid cells isolated from fresh fibroid tissue were used to examine the expression of several MMPs, tissue inhibitors of metalloproteinases (TIMP) 1 and 2 and the activities of MMP-2 and MMP-9 after 1,25(OH)₂D3 treatment." | ( Al-Hendy, A; Halder, SK; Osteen, KG, 2013) |
| "Use of letrozole reduced fibroid volume by 46% and use of a gonadotrophin-releasing hormone (GnRH) agonist (GnRHa) by 32% after 12 weeks of treatment; these proportions were not significantly different." | ( Lu, D; Navaratnam, K; Shi, G; Song, H, 2013) |
| "Given the heterogeneity of fibroids and the lack of effective treatments in controlling their growth, the identification of signals that stimulate the onset and growth of these fibroids opens doors to the development of new therapies." | ( Cancelo Hidalgo, MJ, 2013) |
| "The treatment aim was fibroid shrinkage and the primary definitions and outcomes are published elsewhere; here the secondary outcome measure of vaginal bleeding pattern is described." | ( Barlow, DH; Bestel, E; Fauser, BC; Lumsden, MA; Terrill, P, 2014) |
| "Cell viability and proliferation of uterine leiomyoma cells were significantly reduced by flavopiridol treatment in a dose-dependent manner." | ( Baek, JW; Cha, SD; Cho, CH; Choi, ES; Chung, R; Kwon, SH; Lee, GH; Lee, HG; Park, WJ; Shin, SJ, 2014) |
| "Forty patients with uterine fibroids from the Department of Ultrasonography in our hospital were randomly divided into 2 groups of the same size: group H, which only underwent high-intensity focused ultrasound treatment; and group H + A, which underwent sonographically guided intratumoral ethanol injection therapy first and then high-intensity focused ultrasound treatment the following day." | ( Chen, J; Jiang, K; Ma, J; Mu, D; Wang, J; Yang, H; Yang, Z; Yu, Y; Zhang, H; Zhang, R; Zhang, Y, 2014) |
| "In the treatment of uterine fibroids, high-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection requires less treatment time and a lower dose than simple high-intensity focused ultrasound treatment and significantly reduces the pain and side effects commonly experienced by patients." | ( Chen, J; Jiang, K; Ma, J; Mu, D; Wang, J; Yang, H; Yang, Z; Yu, Y; Zhang, H; Zhang, R; Zhang, Y, 2014) |
| "In both the UPA and UAE groups, fibroid volumes decreased significantly after treatment in comparison with baseline volumes obtained prior to treatment." | ( Czuczwar, P; Milart, P; Paszkowski, T; Szkodziak, P; Wozniak, S; Wozniakowska, E; Wrona, W, 2015) |
| "Twenty patients with 22 symptomatic fibroids were treated with sonographically guided high-intensity focused ultrasound under no anesthesia." | ( Ahuja, AT; Cheung, EC; Ho, SS; Leung, JH; Leung, VY; Tong, MM; Wong, AS; Yu, SC, 2014) |
| "In women programmed for surgical treatment for uterine fibroids, oral UA treatment (5 or 10 mg/day) controls symptoms, reduces tumor size and improves quality of life as compared to placebo and is not inferior to monthly intramuscular injection of leuprolide acetate for 3 months." | ( Pérez-López, FR, 2015) |
| "Incident use of fibroid treatments was determined through annual interviews." | ( Gregorich, SE; Jackson, R; Jacoby, A; Jacoby, VL; Kuppermann, M; Learman, LA; Schembri, M, 2014) |
| "Immortalized human uterine fibroid (human uterine leiomyoma [HuLM]) cells were treated with 1,25(OH)2D3 and assayed for the expression and localization of the aforementioned receptors and SRCs using Western blot, immunohistochemistry, immunofluorescence, and immunoprecipitation assays." | ( Al-Hendy, A; Diamond, MP; El-Sohemy, A; Halder, SK, 2015) |
| "In the treatment of symptomatic uterine fibromas, embolization of the uterine arteries performed via a transbrachial approach was shown to be safe and technically valid with regard to reducing the overall time of the intervention, ease of selective catheterisation, and shorter times spent in hospital, as well as being better accepted by patients." | ( Agresti, P; Damiani, P; Di Felice, M; Di Giampietro, I; Marasca, E; Menichini, G; Miele, V; Moreschi, E; Pieri, S; Sessa, B; Trinci, M, 2015) |
| "UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life." | ( Bizzarri, N; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Scala, C; Tafi, E; Venturini, PL, 2015) |
| "Then we isolated and cultured uterine fibroid cells, designed the siRNA of AK000953 to silence its expression in uterine fibroid cells, and detected the treatment effect of danazol and AK000953 siRNA on cell proliferation, cell apoptosis, and cell invasion." | ( Li, S; Liang, J; Liu, H; Lu, X; Niu, L; Wang, Q; Zhang, Y; Zhao, X, 2015) |
| "Uterine fibroids are extremely common, and can cause significant morbidity, yet the exact cause of these tumors remains elusive and there are currently no long-term treatments available." | ( Bulun, SE; Moravek, MB, 2015) |
| "About one-third of women with fibroids present with symptoms severe enough to warrant treatment." | ( Naval, R; Naval, S; Rane, J, 2017) |
| "The patient presented with uterine fibroids and heavy menstrual bleeding, and was treated with ulipristal acetate over three 90-day courses." | ( Bateman, J; Bougie, O; Islam, S; Singh, S, 2017) |
| "Uterine fibroids are a common problem for reproductive-aged women, yet little comparative effectiveness research is available to guide treatment choice." | ( AbdElmagied, AM; Barnard, EP; Borah, BJ; Gorny, KR; Hesley, GK; Jacoby, VL; Kohi, MP; Laughlin-Tommaso, SK; Leppert, PC; Miller, MJ; Nieves, A; Peterson, LG; Price, TM; Stewart, EA; Vaughan, LE; Weaver, AL; Woodrum, DA, 2017) |
| "Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs." | ( Bumbuliene, Ž; Costa, AR; Gemzell-Danielsson, K; Heikinheimo, O; Heweker, A; Hudeček, R; Jacquemyn, Y; Melis, GB; Parashar, P; Rechberger, T; Sánchez, AC; Seitz, C; van Aken, B; Zatik, J, 2017) |
| "Compared to myometrium, uterine leiomyoma cells showed an increase in PRT mRNA expression when treated with E2, and increase in PRB mRNA expression when treated with E2 and P4." | ( Branchini, G; Brum, IS; Capp, E; Corleta, HVE; Pizzolato, LS; Sant'Anna, GDS, 2017) |
| "After UAE, the diameter of uterine fibroids was significantly smaller than that before treatment, and the TGF-β level significantly decreased (p < ." | ( Huang, Y; Shen, T; Shi, H; Song, Q; Xu, Q; Xu, Y, 2017) |
| "As a treatment of fibroids, UPA (5 mg daily dose) should be administered for periods of three months as a pre-surgical strategy, reducing bleeding and fibroid size and facilitating surgery." | ( Gilles, C; Manigart, Y; Pazzaglia, E; Praet, J; Rozenberg, S; Vandromme, J, 2017) |
| "A mouse model of uterine leiomyomas was established by estradiol benzoate, followed by treatment with increasing doses of PTX." | ( Hao, T; Li, Y; Liu, H; Sheng, L; Tang, N; Wang, J; Zhang, Y, 2017) |
| "The 143 patients with solitary uterine fibroids were assigned to four groups: 30 patients were treated using only HIFU; the other patients were pretreated with same dosage of SonoVue and 32, 38 and 43 were treated with HIFU at 1-, 3-, and 5-minutes after administration of SonoVue, respectively." | ( Bai, J; Cheng, C; Huang, G; Xiao, Z; Zhang, L, 2017) |
| "Treatment with UPA decreased fibroid volume in placebo-controlled, randomized trials." | ( Britten, J; Catherino, WH; Cox, J; Lewis, T; Malik, M, 2018) |
| "In all, 372 pregnant women with uterine fibroids who were treated at the Affiliated Provincial Hospital of Shandong University were included in this study." | ( Huang, XY; Liu, M; Liu, RH; Mu, YL; Wang, S; Wang, XT; Wu, YR; Zhao, N, 2017) |
| "The percentage of uterine fibroids with red degeneration was lower in the treatment group than in the control group, but the difference was not statistically significant." | ( Huang, XY; Liu, M; Liu, RH; Mu, YL; Wang, S; Wang, XT; Wu, YR; Zhao, N, 2017) |
| "Young women developing fibroids and/or women with large fibroids may be resistant to ulipristal acetate therapy." | ( Brun, JL; Froeliger, A; Monseau-Thiburce, AC; Rajaonarison, J; Randriamboavonjy, R; Vogler, A, 2018) |
| "When the fibroids were divided according to their localization, all had significant volume reduction after therapy, but type 5 had the highest decrease (42%) compared to other fibroid types (P = ." | ( Baggio, S; Franchi, M; Galeone, F; Pomini, P; Presti, F; Raffaelli, R; Santi, L, 2018) |
| "Type 5 fibroids seem to have the most major response to treatment." | ( Baggio, S; Franchi, M; Galeone, F; Pomini, P; Presti, F; Raffaelli, R; Santi, L, 2018) |
| "Uterine leiomyomas (fibroids or myomas) are the most common benign tumors of premenopausal women and new medical treatments are needed." | ( Castellucci, C; Ciarmela, P; Ciavattini, A; Fiorini, R; Frega, NG; Gagliardi, R; Giannubilo, SR; Greco, S; Islam, MS; Pacetti, D; Zannotti, A, 2018) |
| "Of the compared fibroid treatment methods UAE seems to have the greatest impact on ovarian function and should not be offered to patients concerned about their ovarian function." | ( Czuczwar, P; Milart, P; Paszkowski, T; Stepniak, A; Wozniak, S, 2018) |
| "156 women with symptomatic uterine fibroids were treated using MR-guided HIFU procedure." | ( Filipowska, J; Krol, P; Kubaty, A; Lozinski, T; Wegrzyn, P, 2018) |
| "In women with uterine leiomyomas, once-daily treatment with relugolix, an oral gonadotropin-releasing hormone antagonist, demonstrated noninferiority to monthly leuprorelin for improvement of heavy menstrual bleeding at 6-12 weeks of treatment, had a more rapid effect on menstrual bleeding, and was generally well tolerated." | ( Enya, K; Hoshiai, H; Kudou, K; Osuga, Y; Tanimoto, M, 2019) |
| "A total of 139 patients affected by uterine fibromatosis undergoing conservative ulipristal acetate treatment were enrolled in this prospective observational cohort study." | ( Barra, V; Bellone, E; Biscione, A; Luisi, S; Severi, FM, 2020) |
| "Clinical literature related to the treatment of uterine fibroids by Chinese National Knowledge Infrastructure (CNKI) from 2004 to 2018 were searched, and the literature meeting the requirements were selected according to the inclusion criteria and exclusion criteria." | ( Chen, X; Deng, G; Liu, R; Xuan, J; Zheng, Y, 2020) |
| "Uterine fibroid embolisation (UFE) is an effective treatment for fibroids." | ( Anthony, S; Elzein, A; Husainy, MA; Makris, GC; Patel, R; Saibudeen, A; Uberoi, R; Wigham, A, 2019) |
| "Though rare, fibroids should remain on the differential as the cause of abnormal uterine bleeding in the adolescent population, particularly if symptoms persist despite initial therapy." | ( Kumura, NDS; Siarezi, S, 2020) |
| "Submucosal fibroids had a higher response rate to treatment (i." | ( Agostini, A; Netter, A; Pauly, V; Pivano, A; Siles, P; Vidal, V, 2019) |
| "Immortalized human uterine fibroid cells (UtLM) and hepatocytes (HepG2) were treated with the synthetic glucocorticoid dexamethasone and/or ulipristal." | ( Al-Hendy, A; Anam, A; Burman, A; Flannery, C; Kisanga, EP; Millard, CEF; Small, B; Whirledge, S, 2020) |
| "Although uterine leiomyomas are the most common benign uterine tumors in women, there is no effective therapy that can also preserve the uterus and maintain fertility." | ( Choi, HJ; Hwang, WY; Jung, MH; Kim, EJ; Kim, KS; Lee, JW, 2020) |
| "Primary and immortalized human uterine leiomyoma cells were treated with simvastatin at increasing concentrations (0." | ( Afrin, S; Borahay, MA; Catherino, WH; Islam, MS; Malik, M; Patzkowsky, K; Segars, JH, 2020) |
| "The presence of submucous fibroids strongly impacts on IVF results, therefore, these patients should be considered for surgical or medical treatment." | ( Centini, G; De Leo, V; Morgante, G; Orvieto, R; Troìa, L, 2020) |
| "Infertile patients with submucosal fibroid (Type 1 and Type 2 according to FIGO classification) were enrolled in the study as fibroids group and received 1 to 3 treatment cycles of UPA, according to their response, as reflected by fibroid volume reduction and restoration of normal uterine cavity." | ( Centini, G; De Leo, V; Morgante, G; Orvieto, R; Troìa, L, 2020) |
| "To evaluate symptomatic uterine fibroid outcomes following at least one course of ulipristal acetate (UPA) 5 mg/day therapy in the hospital setting, during the year 2017." | ( Águas, F; Gomes, C; Guerreiro, F; Martinho, M; Ponte, C; Silva, D; Vilhena, V, 2020) |
| "17 premenopausal women with fibroids considered to be treated with MR-HIFU and 11 women with no fibroids were enrolled in the study." | ( Blanco Sequeiros, R; Joronen, K; Komar, G; Otonkoski, S; Perheentupa, A; Sainio, T; Saunavaara, J; Suomi, V, 2020) |
| "Primary cultured cell lines of uterine leiomyoma were treated with 0." | ( Li, Z; Ren, M; Shen, Y; Xu, X; Yin, H, 2021) |
| "Women with uterine fibroids were divided into 2 treatment groups: the UPA (5 mg/day) and GnRH agonist groups." | ( Yoon, EL; Yuk, JS, 2021) |
| "Among the patients with uterine fibroids,17 207 patients were treated with GnRH agonists and 20 926 patients with UPA." | ( Yoon, EL; Yuk, JS, 2021) |
| "Signal intensity (SI) of predominant fibroid (F1) on T2-weighted (T2W) images is useful for predicting the volume reduction response after gonadotropin-releasing hormone (GnRH)-agonist treatment." | ( Alqahtani, A; An, H; Han, K; Kim, MD; Lee, WJ; Moon, S; Won, YR, 2022) |
| "Data from 30 patients with a large fibroid and MRI results both before and after GnRH-agonist treatment were retrospectively analyzed." | ( Alqahtani, A; An, H; Han, K; Kim, MD; Lee, WJ; Moon, S; Won, YR, 2022) |
| "After GnRH-agonist treatment for large fibroids, UAE is effective to achieve complete infarction of fibroids." | ( Alqahtani, A; An, H; Han, K; Kim, MD; Lee, WJ; Moon, S; Won, YR, 2022) |
| "Ulipristal acetate (UPA) is a medical treatment for uterine fibroids and was authorized for surgical pre-treatment in 2012 after the conduct of the PEARL I and II randomized controlled trials and for intermittent treatment after the observational PEARL III and IV trials." | ( Bet, PM; Clark, TJ; de Lange, ME; Hehenkamp, WJK; Huirne, JAF; Middelkoop, MA; Mol, BWJ, 2022) |
| "Uterine leiomyomas, or fibroids, are estrogen dependent benign tumor in women, however, they have limited treatment options." | ( Afrin, S; Borahay, MA; Charewycz, N; El Sabeh, M; Miyashita-Ishiwata, M; Singh, B, 2022) |
| "The add-on use of oxytocin in uterine leiomyomas patients undergoing HIFU and ultrasound-guided intratumoral ethanol injection could not improve treatment effect." | ( Chen, J; Ma, J; Wang, Q; Yang, Z; Zhang, B; Zhang, H; Zhang, R; Zhang, Y, 2022) |
| "In addition, the fibroid volume of the observation group before treatment and 3, 6, and 12 months after treatment were also analyzed." | ( Li, Y; Pu, Y; Ren, Y, 2023) |
| "Eligible women with uterine fibroid-associated heavy menstrual bleeding (menstrual blood loss >80 mL per cycle) were randomly assigned in a 1:1:1:1:1 ratio to one of five masked treatments: (1) placebo, (2) 100 mg linzagolix per day alone, (3) 100 mg linzagolix per day with once-per-day hormonal add-back therapy (1 mg oestradiol and 0·5 mg norethisterone acetate), (4) 200 mg linzagolix per day alone, or (5) 200 mg linzagolix per day with once-per-day hormonal add-back therapy (1 mg oestradiol and 0·5 mg norethisterone acetate)." | ( Al-Hendy, A; Archer, D; Bestel, E; Bradley, L; Donnez, J; Garner, E; Gotteland, JP; Humberstone, A; Loumaye, E; Marsh, E; Petraglia, F; Stewart, EA; Taylor, HS; Terrill, P; Watts, N, 2022) |
| "Women with uterine leiomyoma-associated heavy menstrual bleeding who completed any treatment arm in either the LIBERTY 1 or LIBERTY 2 trial were eligible to enroll in a 28-week long-term extension study." | ( Al-Hendy, A; Li, Y; Lukes, AS; McKain, L; Poindexter, AN; Stewart, EA; Venturella, R; Villarroel, C; Wagman, RB, 2022) |
| "More women with uterine fibroids taking relugolix combination therapy for 24 weeks were likely to have fewer uterine fibroid symptoms than women receiving placebo." | ( Al-Hendy, A; Arjona Ferreira, JC; Critchley, HO; Langenberg, AG; Li, Y; Lukes, AS; McKain, L; Poindexter, AN; Stewart, EA; Venturella, R; Villarroel, C; Wagman, RB, 2023) |
| "Viability of myometrial and fibroid cells was not greatly affected by EGCG treatment (1-200 µM)." | ( Brennan, JT; Islam, MS; Parish, M; Segars, JH; Winer, BL, 2023) |
| "Limiting the extent of fibroid necrosis after treatment is a reasonable goal to minimize the risk of secondary bacterial infection and adhesiogenesis as procedural sequelae." | ( Hirsch, AM; Raphael, YR; Siedhoff, MT, 2023) |
| "Women with uterine fibroid-associated heavy menstrual bleeding who completed the 24-week LIBERTY 1 or 2 trials, followed by the 28-week long-term extension study (up to 52 weeks total treatment), and who met the responder criteria (menstrual blood loss volume <80 mL and ≥50% reduction from pivotal study baseline at week 48 [week 24 of long-term extension]) were randomized in a 1:1 ratio to either blinded treatment with relugolix combination therapy or placebo for 52 weeks (total treatment period, 104 weeks)." | ( Al-Hendy, A; Arjona Ferreira, JC; Li, Y; Lukes, AS; Soulban, G; Venturella, R; Wagman, RB, 2023) |
| "Human uterine leiomyoma (HuLM) cells were treated with different concentrations of Crila, alone or in combination with EGCG, and several experiments were employed." | ( Al-Hendy, A; Ali, M; Bai, T; McKinney, S; Somers, B; Yang, Q, 2023) |